These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 28734944)

  • 1. Triple-Negative Breast Cancer: Next-Generation Sequencing for Target Identification.
    Marotti JD; de Abreu FB; Wells WA; Tsongalis GJ
    Am J Pathol; 2017 Oct; 187(10):2133-2138. PubMed ID: 28734944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of CHD4-β1 integrin axis as a prognostic marker in triple-negative breast cancer using next-generation sequencing and bioinformatics.
    Ou-Yang F; Pan MR; Chang SJ; Wu CC; Fang SY; Li CL; Hou MF; Luo CW
    Life Sci; 2019 Dec; 238():116963. PubMed ID: 31639396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
    Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
    BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic EP300-G211S mutations are associated with overall somatic mutational patterns and breast cancer specific survival in triple-negative breast cancer.
    Bemanian V; Noone JC; Sauer T; Touma J; Vetvik K; Søderberg-Naucler C; Lindstrøm JC; Bukholm IR; Kristensen VN; Geisler J
    Breast Cancer Res Treat; 2018 Nov; 172(2):339-351. PubMed ID: 30132219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of Triple-Negative Breast Cancer.
    Derakhshan F; Reis-Filho JS
    Annu Rev Pathol; 2022 Jan; 17():181-204. PubMed ID: 35073169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of triple-negative breast cancer.
    Kumar P; Aggarwal R
    Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.
    Wang XZ; Liu Q; Sun JJ; Zuo WS; Hu DW; Ma SG; Mu DB; Yu ZY
    Genet Mol Res; 2015 Apr; 14(2):4282-90. PubMed ID: 25966200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic gene mutation analysis of triple negative breast cancers.
    Dillon JL; Mockus SM; Ananda G; Spotlow V; Wells WA; Tsongalis GJ; Marotti JD
    Breast; 2016 Oct; 29():202-7. PubMed ID: 27397723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Markers in Triple-Negative Breast Cancer.
    Sporikova Z; Koudelakova V; Trojanec R; Hajduch M
    Clin Breast Cancer; 2018 Oct; 18(5):e841-e850. PubMed ID: 30146351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
    Safarpour D; Tavassoli FA
    Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology.
    Weisman PS; Ng CK; Brogi E; Eisenberg RE; Won HH; Piscuoglio S; De Filippo MR; Ioris R; Akram M; Norton L; Weigelt B; Berger MF; Reis-Filho JS; Wen HY
    Mod Pathol; 2016 May; 29(5):476-88. PubMed ID: 26939876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
    Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
    Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple-negative breast carcinoma: current and emerging concepts.
    Schmadeka R; Harmon BE; Singh M
    Am J Clin Pathol; 2014 Apr; 141(4):462-77. PubMed ID: 24619745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.